ArticleMaterials today. Bio2026
A degradable PEGDA-dopamine hydrogel with ROS scavenging capacity supports flexible design for nerve repair.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peripheral nerve injury remains a significant clinical challenge, with current therapeutic material limited by inadequate degradation control, insufficient oxidative stress management, and poor adaptability to patient-specific contexts. We developed a degradable poly (ethylene glycol) diacrylate-dopamine-acrylamide hydrogel platform that addresses these limitations, enabling tunable bulk degradation with concomitant dopamine release. By systematically varying the ratio of degradable crosslinker poly (ethylene glycol) diacrylate-dopamine, we generated composition-defined degradation profiles spanning 2 months with corresponding dopamine release patterns. The hydrogels exhibited mechanical properties comparable to native peripheral nerves while maintaining exceptional flexibility through multiple bending and torsional cycles. In vitro validation demonstrated that dopamine-releasing hydrogels effectively scavenged intracellular reactive oxygen species in both human Schwann cells and endothelial cells under oxidative challenge, while modulating Schwann cell gene expression in a pattern consistent with a transition from repair toward a pro-remyelination transcriptional profile, and shifting endothelial gene expression toward a pro-angiogenic transcriptional pattern. Using digital light processing bioprinting we fabricated customizable nerve wraps, tubular structures, and microarchitectures with internal channels that directed cell alignment, while controlled FITC-dextran release validated localized delivery capabilities. These findings establish a multifunctional hydrogel platform combining programmable degradation, antioxidant functionality, and cellular microenvironment control for peripheral nerve repair applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.